Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
NCT04541589
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
206
Enrollment
INDUSTRY
Sponsor class
Conditions
Sjogren's Syndrome
Interventions
DRUG:
Iscalimab
OTHER:
Placebo
Sponsor
Novartis Pharmaceuticals